ADAM-MD is a operating name for Systems Modeling and Automated Report Technologies for Medical Decisions (SMART-MD), LLC. SMART-MD was founded in Pittsburgh, PA and incorporated in 2013 as a Pennsylvania-based LLC. Formation of the company included the contribution of CyberGene Diagnostics, Inc. which owned a patent on a method to test for mutations in the cationic trypsinogen gene (PRSS1) and to test for genetic etiologies for pancreatic diseases. The vision of SMART-MD is to integrate detailed patient information, including genetic testing such as PRSS1 variants, into useful reports that could be delivered to health care professionals linked to educational opportunities. This vision became a reality with the complementary skills and common values of the founders, linking technology, medicine and marketing together.
The implementation of the vision included the formation of two Divisions of SMART-MD: Advanced Diagnostics And Modeling for Medical Decisions (ADAM-MD), and allPANCREAS a clinical research, product development and marketing division focusing on complex pancreatic disorders. These divisions are based on the HudsonAlpha Institute for Biotechnology (HAIB) campus, to benefit from the innovative environment in the field of genomic technology and sciences across a spectrum of biological problems. HudsonAlpha's state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators.
The SMART-MD LLC Divisions are designed to benefit multiple future customers in a rapidly changing health care environment. Opportunities are available for health care organizations and ACOs, physician groups, pharmaceutical companies and patient groups. SMART-MD LLC is in the business of predicting better health, with a vision of health for life.